Article

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databases

2025-05-05

Abstract excerpt

<h4>Aims: </h4> Fruquintinib, a highly selective small-molecule tyrosine kinase inhibitor targeting the vascular endothelial growth factors (VEGF)-1, -2, and -3, has demonstrated significant efficacy in prolonging progression-free survival and overall survival in patients with refractory metastatic colorectal cancer. This study aims to generate robust scientific evidence for clinical practice and regulatory decisi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a4d4be76-a341-54d6-807e-b22dad0a6a61
DOI: 10.22541/au.174644893.35545060/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesDOI 10.22541/au.174644893.35545060/v1Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read

Real-world pharmacovigilance study of voclosporin based on FAERS and VigiBaseSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.Semantic proximity Read

Pharmacovigilance Insights into Gastrointestinal Adverse Events of JAK Inhibitors: FAERS Signal Detection with Clinical and Pharmacological ImplicationseSemantic proximity Read

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read

Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting systemSemantic proximity Read